Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | POLA1 | P09884 | 1/20 | 0.50 |
| ▸ | POLD1 | P28340 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2293561 | 0.93 | POLB (0.51) | POLBPOLA1POLD1 | |
| SCHEMBL18844329 | 0.93 | POLB (0.51) | POLBPOLA1POLD1 | |
| SCHEMBL26779532 | 0.92 | POLB (0.47) | POLBPOLA1POLD1 | |
| SCHEMBL15115325 | 0.92 | POLB (0.49) | POLBPOLA1POLD1 | |
| SCHEMBL2301090 | 0.92 | POLB (0.52) | POLBPOLA1POLD1 | |
| SCHEMBL12378786 | 0.91 | POLB (0.54) | POLBPOLA1POLD1 | |
| SCHEMBL14606222 | 0.90 | POLB (0.53) | POLBPOLA1POLD1 | |
| SCHEMBL8600185 | 0.89 | POLB (0.56) | POLBPOLA1POLD1 | |
| SCHEMBL8600188 | 0.89 | POLB (0.56) | POLBPOLA1POLD1 | |
| SCHEMBL2296337 | 0.89 | POLB (0.49) | POLBPOLA1POLD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162251-A1 | NUCLEOTIDE ANALOGUES | QIAGEN SCIENCES, LLC | 2022-05-26 | — | — | US | disclosed |
| US-11046726-B2 | Nucleotide analogues | QIAGEN SCIENCES, LLC (US) | 2021-06-29 | — | — | US | disclosed |
| US-20180208774-A1 | NUCLEOTIDE ANALOGUES | IsoPlexis Corporation | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046726-B2 | Nucleotide analogues | NT5C3B, SAMHD1, DUT | POLB 28/4885POLA1 171/4885POLD1 125/4885 |
| US-20220162251-A1 | NUCLEOTIDE ANALOGUES | NT5C3B, SAMHD1, DUT | POLB 28/4885POLA1 171/4885POLD1 125/4885 |
| US-20180208774-A1 | NUCLEOTIDE ANALOGUES | NT5C3B, SAMHD1, DUT | POLB 28/4885POLA1 171/4885POLD1 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.